7 Stocks on the upsurge – ALU, FLK, WTC, DCC, NEU, APX and SVW

7 Stocks that upsurge

Below are 7 stocks that have seen a significant rise in stock prices as at August 22, 2018.

ALTIUM LIMITED (ASX: ALU): Altium Designer and TASKING are part of its products and the company has business in the regions – Asia Pacific, Americas, the Middle East and Africa, Europe, and Emerging Markets. The stock of the company was trading at a market price of $28.75 as on August 22, 2018 and has seen a daily price change or a rise of $6.9 or a percentage change of 31.7%. The stock has seen a performance change of 151.79% over the past 12 months. The company recorded the full year performance with 26% growth in revenue and 34% growth in the profit. Company also recorded an EBITDA margin of 32.0%. The result was primarily driven by a 10% increase in subscriber seats that moved up to 37,917. With 6,321 new licenses sold there has been 15% increase in the Altium designer seats.

FOLKESTONE LIMITED (ASX: FLK): The stock of the company traded at a market price of $1.39 as on August 22, 2018 and has seen a daily price change or a rise of $0.28 or a percentage change of 25.23%. The stock has seen a performance change of -0.47% over the past 12 months. The company’s expertise is across the residential, non-residential and real estate related social infrastructure sectors. The company’s FY18 NPAT is up by 3.3% to $13.9 million and EPS is up to 9.4c up by 3.3%. While the company continues its strategy of growing its funds management platform, FUM increased by 26.1% to $1.6 billion. The ordinary dividend is up by 9.1% to 3.0c. Meanwhile, the stock price also boosted by the news that Charter Hall Group has agreed to acquire FLK for $205 million, and the acquisition is expected to be funded by cash from available investment capacity.

WISETECH GLOBAL LIMITED (ASX: WTC): WTC is an information technology company that provides software solutions globally to the logistics industry. WiseTech is a leading provider of software to the logistics services globally with presence in 130 countries and more than 7,000 customers, and the company has more than 44 Billion data transactions annually.  The stock of the company was trading at a market price of $19.9 as on August 22, 2018 and has seen a daily price change or a rise of $4.26 or a percentage change of 27.3%. The stock has seen a performance change of 121.53% over the past 12 months. The company has recently announced the appointment of a new independent Nonexecutive chairperson – Andrew Harrison. The most recent acquisition of the company was Pierbridge Inc with a transaction value of $59.40 million and the group announced it on June 21, 2018. It posted a powerful revenue growth of $221.6 million for FY18 which is up 44% compared to FY17 while FY18 EBITDA soared up 45% and NPAT was up 28% given the healthy global business performance.

DIGITALX LIMITED (ASX: DCC): It is a software solutions company disrupting the payments industry. The company was incorporated in 1988 and is based in Milligan Street, Perth, Australia. The stock of the company was trading at a market price of $0.135 as on August 22, 2018 and has seen a daily percentage change of 12.5%. The stock has seen a performance change of 200.00% over the past 12 months. It has a total cash of US$ 5.3 million and digital assets trading on exchanges of approximately US$5 million as at Quarter ending March 31, 2018. DigitalX has been appointed as corporate advisors to multiple ICO’s in major global markets. For instance, DigitalX is appointed by Bitfinex as a Crypto asset listing advisor. At June quarter end, DigitalX had listed crypto assets, fund units and cash of over US $10 million.

NEUREN PHARMACEUTICALS LIMITED (ASX: NEU): The stock of the company was trading at a market price of $1.265 as on August 22, 2018 and has seen a daily percentage change of 12.95% with the news of appointing a new auditor – Grant Thornton New Zealand. The stock has otherwise seen a performance change of -15.15% over the past 12 months. The group signed a license agreement with ACADIA Pharmaceuticals Inc under which it will receive an initial payment of US$10 million. Other than the trofinetide sales, Neuren is also eligible to receive up to US $105 million on achievement of US development milestones and up to US$350 million on achievement of thresholds of total annual net sales of trofinetide.

Sponsored ad by Kalkine

APPEN LIMITED (ASX: APX): The stock of the company was trading at a market price of $12.860 as on August 22, 2018 while it is close to its 52-week high and has seen a daily price change or a rise of $1.380 or a percentage change of 12.02%. The stock has seen a performance change of 174.64% over the past 12 months. The company has announced that for the half year ended 30 June 2018, Appen will release its earnings information later next week on August 28, 2018. The share price is soaring with the rise seen for other tech stocks as well.

SEVEN GROUP HOLDINGS LIMITED (ASX: SVW): The stock of the company was trading at a market price of $22.06 as on August 22, 2018 and has seen a daily price change or a rise of $1.770 or a percentage change of 8.7%. The stock has seen a performance change of 71.95% over the past 12 months. From the continuing operations, the company achieved FY18 Group EBIT of $497 million which is a growth rate of 67 percent on FY17. The statutory net profit after tax as a result was $405 million and the company declared a final fully franked ordinary dividend of 21 cents per share. However, the group’s debt increased owing to acquisitions and higher investments.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report

LEAVE A REPLY

Please enter your comment!
Please enter your name here